Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
GILDthis companyGilead Sciences, Inc.	$168.96	17.94×	6.73×	5.19×	12.52×	-17.4%	78.8%	39.7%	28.9%	37.5%	20.3%	6.2%	1.1×	1.28×	11.43×	1.55×	2.6%	5	3.97	1	C-
ABBVAbbVie Inc.	$292.26	96.41×	-123.96×	6.63×	26.61×	-55.6%	70.2%	32.8%	6.9%	-129.2%	13.0%	4.4%	-21.12×	3.62×	6.94×	0.67×	2.9%	7	2.9	1	C-
JNJJohnson & Johnson	$280.24	18.82×	6.18×	5.35×	12.97×	7.8%	67.9%	27.2%	28.5%	32.9%	13.7%	3.9%	0.59×	0.69×	26.36×	1.03×	2.5%	7	5.49	3	B+
LLYEli Lilly and Company	$1,399.67	46.58×	36.37×	14.81×	31.57×	-47.2%	83.0%	45.6%	31.7%	77.8%	30.2%	0.9%	1.6×	1.12×	37.34×	1.58×	0.6%	7	9.47	3	B
MRKMerck & Co., Inc.	$147.51	14.42×	5.01×	4.06×	10.59×	19.4%	72.0%	36.2%	28.1%	34.7%	18.3%	4.7%	0.96×	1.27×	17.31×	1.54×	3.1%	6	3.99	1	C-
PFEPfizer Inc.	$29.33	18.31×	1.64×	2.26×	12.38×	19.3%	74.3%	27.8%	12.4%	9.0%	10.0%	6.4%	0.78×	3.95×	6.52×	1.16×	6.9%	6	2.16	3	B
Peer median	—	18.82×	5.01×	5.35×	12.97×	7.8%	72.0%	32.8%	28.1%	32.9%	13.7%	4.4%	0.78×	1.27×	17.31×	1.16×	2.9%	7	3.99	3	—